WO2010147792A2 - Compounds which selectively modulate the cb2 receptor - Google Patents
Compounds which selectively modulate the cb2 receptor Download PDFInfo
- Publication number
- WO2010147792A2 WO2010147792A2 PCT/US2010/037697 US2010037697W WO2010147792A2 WO 2010147792 A2 WO2010147792 A2 WO 2010147792A2 US 2010037697 W US2010037697 W US 2010037697W WO 2010147792 A2 WO2010147792 A2 WO 2010147792A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- ring
- optionally
- chosen
- thiomorpholinyl
- Prior art date
Links
- 0 CC(*)(*)C(N)=O Chemical compound CC(*)(*)C(N)=O 0.000 description 2
- FICAQKBMCKEFDI-UHFFFAOYSA-N Cc1n[o]c(C)c1 Chemical compound Cc1n[o]c(C)c1 FICAQKBMCKEFDI-UHFFFAOYSA-N 0.000 description 2
- FUOOLUPWFVMBKG-UHFFFAOYSA-N CC(C)(C(O)=O)N Chemical compound CC(C)(C(O)=O)N FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 1
- JAWOFBIPDFVOLC-UHFFFAOYSA-N CC(C)(C(O)=O)N(C)CC1CCOCC1 Chemical compound CC(C)(C(O)=O)N(C)CC1CCOCC1 JAWOFBIPDFVOLC-UHFFFAOYSA-N 0.000 description 1
- TXWJJRKRRYBWKM-UHFFFAOYSA-N CC(C)(C(O)=O)NCC1CCOCC1 Chemical compound CC(C)(C(O)=O)NCC1CCOCC1 TXWJJRKRRYBWKM-UHFFFAOYSA-N 0.000 description 1
- YRBHQZFQVGVYPA-KJQUIYBXSA-O CC(C)(CO)C(/C=C(/NC(C(C)(C)N(C)C(CC1CCOCC1)=O)=O)\O)=[NH2+] Chemical compound CC(C)(CO)C(/C=C(/NC(C(C)(C)N(C)C(CC1CCOCC1)=O)=O)\O)=[NH2+] YRBHQZFQVGVYPA-KJQUIYBXSA-O 0.000 description 1
- DKXLETRZGOQGOG-UHFFFAOYSA-N CC(C)(CO)c1n[o]c(NC(C(C)(C)N(C)CCC2COCC2)=O)c1 Chemical compound CC(C)(CO)c1n[o]c(NC(C(C)(C)N(C)CCC2COCC2)=O)c1 DKXLETRZGOQGOG-UHFFFAOYSA-N 0.000 description 1
- GPUHBFAQMSFPQH-SAKDXEPDSA-O CC(C)(COC1OCCCC1)C(/C=C(/NC(C(C)(C)Br)=O)\O)=[NH2+] Chemical compound CC(C)(COC1OCCCC1)C(/C=C(/NC(C(C)(C)Br)=O)\O)=[NH2+] GPUHBFAQMSFPQH-SAKDXEPDSA-O 0.000 description 1
- VSDHHWRVEIFJGH-JIECSLGGSA-O CC(C)(COC1OCCCC1)C(/C=C(/NC(C(C)(C)N(C)C(CC1CCOCC1)=O)=O)\O)=[NH2+] Chemical compound CC(C)(COC1OCCCC1)C(/C=C(/NC(C(C)(C)N(C)C(CC1CCOCC1)=O)=O)\O)=[NH2+] VSDHHWRVEIFJGH-JIECSLGGSA-O 0.000 description 1
- ODFCEGYINNMNLX-JSENCJNKSA-O CC(C)(COC1OCCCC1)C(/C=C(/NC(C(C)(C)NC)=O)\O)=[NH2+] Chemical compound CC(C)(COC1OCCCC1)C(/C=C(/NC(C(C)(C)NC)=O)\O)=[NH2+] ODFCEGYINNMNLX-JSENCJNKSA-O 0.000 description 1
- GDQDBACWTLSUBK-UHFFFAOYSA-N CC(C)(COC1OCCCC1)c1n[o]c(NC(C(C)(C)NC)=O)c1 Chemical compound CC(C)(COC1OCCCC1)c1n[o]c(NC(C(C)(C)NC)=O)c1 GDQDBACWTLSUBK-UHFFFAOYSA-N 0.000 description 1
- WEHNYUBPGOKWGB-UHFFFAOYSA-N CC(C)(COCCOC)c1n[o]c(NC(C(C)(C)N(C)CC2CCOCC2)=O)c1 Chemical compound CC(C)(COCCOC)c1n[o]c(NC(C(C)(C)N(C)CC2CCOCC2)=O)c1 WEHNYUBPGOKWGB-UHFFFAOYSA-N 0.000 description 1
- DMGLOLWYSNIZQN-UHFFFAOYSA-N CS(OCCC1COCC1)(=O)=O Chemical compound CS(OCCC1COCC1)(=O)=O DMGLOLWYSNIZQN-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2010260397A AU2010260397A1 (en) | 2009-06-15 | 2010-06-08 | Compounds which selectively modulate the CB2 receptor |
CA2765525A CA2765525A1 (en) | 2009-06-15 | 2010-06-08 | Compounds which selectively modulate the cb2 receptor |
MX2011013152A MX2011013152A (en) | 2009-06-15 | 2010-06-08 | Compounds which selectively modulate the cb2 receptor. |
SG2011092871A SG176864A1 (en) | 2009-06-15 | 2010-06-08 | Compounds which selectively modulate the cb2 receptor |
CN2010800248806A CN102803235A (en) | 2009-06-15 | 2010-06-08 | Compounds which selectively modulate the CB2 receptor |
EP10723895A EP2443100A2 (en) | 2009-06-15 | 2010-06-08 | Compounds which selectively modulate the cb2 receptor |
JP2012516122A JP5492297B2 (en) | 2009-06-15 | 2010-06-08 | Compound that selectively modulates CB2 receptor |
EA201200019A EA201200019A1 (en) | 2009-06-15 | 2010-06-08 | COMPOUNDS WHICH SELECTIVELY MODULATE CB2 RECEPTOR |
AP2011005988A AP2011005988A0 (en) | 2009-06-15 | 2010-06-08 | Compounds which selectively modulate the CB2 receptor. |
BRPI1011668A BRPI1011668A2 (en) | 2009-06-15 | 2010-06-08 | compounds that selectively modulate the cb2 receptor |
MA34453A MA33362B1 (en) | 2009-06-15 | 2010-06-08 | COMPOUNDS THAT SELECTIVELY MODULATE THE CB2 RECEPTOR |
ZA2011/08258A ZA201108258B (en) | 2009-06-15 | 2011-11-10 | Compounds which selectively modulate the cb2 receptor |
IL216348A IL216348A0 (en) | 2009-06-15 | 2011-11-14 | Compounds which selectively modulate the cb2 receptor |
TNP2011000639A TN2011000639A1 (en) | 2009-06-15 | 2011-12-14 | Compounds which selectively modulate the cb2 receptor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18692009P | 2009-06-15 | 2009-06-15 | |
US61/186,920 | 2009-06-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010147792A2 true WO2010147792A2 (en) | 2010-12-23 |
WO2010147792A3 WO2010147792A3 (en) | 2011-09-01 |
Family
ID=42646483
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/037697 WO2010147792A2 (en) | 2009-06-15 | 2010-06-08 | Compounds which selectively modulate the cb2 receptor |
Country Status (23)
Country | Link |
---|---|
US (2) | US8299103B2 (en) |
EP (2) | EP2716635B1 (en) |
JP (1) | JP5492297B2 (en) |
KR (1) | KR20120047211A (en) |
CN (1) | CN102803235A (en) |
AP (1) | AP2011005988A0 (en) |
AR (1) | AR077362A1 (en) |
AU (1) | AU2010260397A1 (en) |
BR (1) | BRPI1011668A2 (en) |
CA (1) | CA2765525A1 (en) |
CL (1) | CL2011003160A1 (en) |
CO (1) | CO6470896A2 (en) |
EA (1) | EA201200019A1 (en) |
EC (1) | ECSP12011583A (en) |
IL (1) | IL216348A0 (en) |
MA (1) | MA33362B1 (en) |
MX (1) | MX2011013152A (en) |
PE (1) | PE20120561A1 (en) |
SG (1) | SG176864A1 (en) |
TN (1) | TN2011000639A1 (en) |
TW (1) | TW201111374A (en) |
WO (1) | WO2010147792A2 (en) |
ZA (1) | ZA201108258B (en) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7928103B2 (en) | 2006-10-17 | 2011-04-19 | Boehringer Ingelheim International Gmbh | Compounds which modulate the CB2 receptor |
US7928123B2 (en) | 2006-09-25 | 2011-04-19 | Boehringer Ingelheim International Gmbh | Compounds which modulate the CB2 receptor |
US8048899B2 (en) | 2008-09-25 | 2011-11-01 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
US8173638B2 (en) | 2006-11-21 | 2012-05-08 | Boehringer Ingelheim International Gmbh | Compounds which modulate the CB2 receptor |
US8178568B2 (en) | 2008-07-10 | 2012-05-15 | Boehringer Ingelheim International Gmbh | Sulfone compounds which modulate the CB2 receptor |
EP2514749A1 (en) * | 2009-12-15 | 2012-10-24 | Shionogi & Co., Ltd. | Oxadiazole derivative having endothelial lipase inhibitory activity |
US8299111B2 (en) | 2006-07-28 | 2012-10-30 | Boehringer Ingelheim International Gmbh | Compounds which modulate the CB2 receptor |
US8299103B2 (en) | 2009-06-15 | 2012-10-30 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
US8329735B2 (en) | 2010-03-05 | 2012-12-11 | Boehringer Ingelheim International Gmbh | Tetrazole compounds which selectively modulate the CB2 receptor |
US8383615B2 (en) | 2009-06-16 | 2013-02-26 | Boehringer Ingelheim International Gmbh | Azetidine 2-carboxamide derivatives which modulate the CB2 receptor |
US8383651B2 (en) | 2009-09-22 | 2013-02-26 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
US8546563B2 (en) | 2007-11-07 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Compounds which modulate the CB2 receptor |
US8629157B2 (en) | 2009-01-05 | 2014-01-14 | Boehringer Ingelheim International Gmbh | Pyrrolidine compounds which modulate the CB2 receptor |
US8846936B2 (en) | 2010-07-22 | 2014-09-30 | Boehringer Ingelheim International Gmbh | Sulfonyl compounds which modulate the CB2 receptor |
US8865744B1 (en) | 2013-05-17 | 2014-10-21 | Boehringer Ingelheim International Gmbh | (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
US8889670B2 (en) | 2009-02-18 | 2014-11-18 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds which modulate the CB2 receptor |
US8957063B2 (en) | 2008-02-21 | 2015-02-17 | Boehringer Ingelheim International Gmbh | Amine and ether compounds which modulate the CB2 receptor |
US9115139B2 (en) | 2009-06-15 | 2015-08-25 | Takeda Pharmaceutical Company Limited | Pyrazinooxazepine derivatives |
US9315454B2 (en) | 2010-01-15 | 2016-04-19 | Boehringer Ingelheim International Gmbh | Compounds which modulate the CB2 receptor |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020056553A1 (en) * | 2018-09-17 | 2020-03-26 | 海门华祥医药科技有限公司 | Method for prepararing heterocyclic compound and salts thereof |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994007607A1 (en) | 1992-09-29 | 1994-04-14 | Boehringer Ingelheim International Gmbh | Atomising nozzle and filter and spray generating device |
WO1997012687A1 (en) | 1995-10-04 | 1997-04-10 | Boehringer Ingelheim International Gmbh | Device of miniaturised construction for producing high pressure in a fluid to be atomised |
WO1997012683A1 (en) | 1995-10-04 | 1997-04-10 | Boehringer Ingelheim International Gmbh | Device for mounting a component exposed to a pressurized fluid |
WO1997020590A1 (en) | 1995-12-05 | 1997-06-12 | Boehringer Ingelheim International Gmbh | Locking mechanism for a spring-actuated device |
WO2008014199A2 (en) | 2006-07-28 | 2008-01-31 | Boehringer Ingelheim International Gmbh | Sulfonyl compounds which modulate the cb2 receptor |
WO2008039645A1 (en) | 2006-09-25 | 2008-04-03 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
WO2009105509A1 (en) | 2008-02-21 | 2009-08-27 | Boehringer Ingelheim International Gmbh | Amine and ether compounds which modulate the cb2 receptor |
Family Cites Families (120)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3116284A (en) * | 1963-12-31 | Chs chj | ||
US3117128A (en) * | 1964-01-07 | Certificate of correction | ||
CH312963A (en) | 1953-03-10 | 1956-03-15 | Sandoz Ag | Process for the production of azo dyes |
GB853799A (en) | 1957-11-21 | 1960-11-09 | Pfizer & Co C | Diquaternary compounds and process of preparing same |
GB884258A (en) | 1958-11-06 | 1961-12-13 | Ciba Ltd | A new quinone derivative |
GB1237126A (en) | 1968-04-10 | 1971-06-30 | Agfa Gevaert Nv | 3-acyl-amino-pyrazolin-5-ones |
US3577462A (en) * | 1968-08-08 | 1971-05-04 | American Home Prod | N-arylalkyl-beta-hydroxy-beta-phenyl-ethylamines and the salts thereof |
US3966809A (en) * | 1973-11-19 | 1976-06-29 | Stauffer Chemical Company | Insect repellent compounds |
US4257954A (en) * | 1978-08-08 | 1981-03-24 | Sterling Drug Inc. | Novel compounds, processes and marking systems |
US4535087A (en) * | 1982-11-19 | 1985-08-13 | Chevron Research Company | N-Substituted phenoxyacetamide fungicides |
US4672065A (en) * | 1982-11-19 | 1987-06-09 | Chevron Research Company | N-substituted phenoxyacetamide fungicides |
US4859707A (en) * | 1983-08-23 | 1989-08-22 | Key Pharmaceuticals, Inc. | Sulfur-substituted phenylacetamides |
JPS6117955A (en) | 1984-07-05 | 1986-01-25 | Mitsubishi Heavy Ind Ltd | Analysis of gaseous ammonia |
JPS6127955A (en) | 1984-07-18 | 1986-02-07 | Hokko Chem Ind Co Ltd | Arylsulfonyl fatty acid amide derivative, its preparation and herbicide |
JPS6127905U (en) | 1984-07-25 | 1986-02-19 | 本田技研工業株式会社 | OHC type internal combustion engine |
JPS61126071A (en) | 1984-11-22 | 1986-06-13 | Hokko Chem Ind Co Ltd | Phenoxyisobutyric acid amide derivative, and agricultural and horticultural fungicide |
DE3600950A1 (en) * | 1986-01-15 | 1987-07-16 | Bayer Ag | 5-ACYLAMIDO-1-ARYL-PYRAZOLE |
WO1991009594A1 (en) * | 1989-12-28 | 1991-07-11 | Virginia Commonwealth University | Sigma receptor ligands and the use thereof |
WO1992009572A1 (en) * | 1990-11-26 | 1992-06-11 | Taisho Pharmaceutical Co., Ltd. | Anilide derivative |
US5362878A (en) * | 1991-03-21 | 1994-11-08 | Pfizer Inc. | Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT) |
CA2077252C (en) | 1992-08-31 | 2001-04-10 | Khashayar Karimian | Methods of making ureas and guanidines, and intermediates therefor |
US5256658A (en) * | 1993-01-15 | 1993-10-26 | Ortho Pharmaceutical Corporation | Angiotensin II inhibitors |
US5428037A (en) * | 1993-04-09 | 1995-06-27 | Syntex Pharmaceuticals, Ltd. | Heterocyclic derivatives in the treatment of Ischaemia and related diseases |
DE4319039A1 (en) * | 1993-06-08 | 1994-12-15 | Bayer Ag | Substituted (2-oxo-1-benzimidazolinyl) -piperidines, process for their preparation and use as anti-retroviral agents |
US5583147A (en) * | 1994-03-23 | 1996-12-10 | The Dupont Merck Pharmaceutical Company | Amides for the treatment of atherosclerosis |
WO1996026925A1 (en) | 1995-03-01 | 1996-09-06 | Banyu Pharmaceutical Co., Ltd. | Arylthioacetamide derivatives |
JP3954127B2 (en) * | 1995-03-14 | 2007-08-08 | クミアイ化学工業株式会社 | Cyclic amide derivatives and herbicides |
WO1997046556A1 (en) | 1996-06-07 | 1997-12-11 | Merck & Co., Inc. | OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY |
US5808453A (en) | 1996-08-21 | 1998-09-15 | Siliconix Incorporated | Synchronous current sharing pulse width modulator |
DE69733142T2 (en) | 1996-09-13 | 2006-03-16 | Schering Corp. | SUBSTITUTED BENZOCYCLOHEPTAPYRIDINE DERIVATIVES USEFUL AS FARNESYL PROTEIN TRANSFERASE INHIBITORS |
CZ92399A3 (en) | 1996-09-27 | 1999-07-14 | Pharmacia & Upjohn Company | {beta}-sulfonylhydroxamic acids functioning as inhibitors of matrix metalloproteinase |
US5968929A (en) * | 1996-10-30 | 1999-10-19 | Schering Corporation | Piperazino derivatives as neurokinin antagonists |
US6048900A (en) * | 1998-02-13 | 2000-04-11 | Bayer Corporation | Amide derivatives and methods for using the same as selective neuropeptide Y receptor antagonists |
CA2470183C (en) * | 1997-02-21 | 2008-01-29 | Bayer Aktiengesellschaft | Intermediates for preparing arylsulphonamides and analogues |
JP2001513771A (en) | 1997-02-27 | 2001-09-04 | アメリカン・サイアナミド・カンパニー | N-hydroxy-2- (alkyl, aryl, or heteroarylsulfanyl, sulfinyl or sulfonyl) -3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors |
US5958940A (en) * | 1997-09-11 | 1999-09-28 | Schering Corporation | Tricyclic compounds useful as inhibitors of farnesyl-protein transferase |
JP2001524462A (en) * | 1997-11-21 | 2001-12-04 | ファーマシア・アンド・アップジョン・カンパニー | Α-Hydroxy, -amino and halo derivatives of β-sulfonylhydroxamic acid as matrix metalloproteinase inhibitors |
US6528529B1 (en) * | 1998-03-31 | 2003-03-04 | Acadia Pharmaceuticals Inc. | Compounds with activity on muscarinic receptors |
US6359009B1 (en) * | 1998-04-08 | 2002-03-19 | Basf Aktiengesellschaft | Substituted anilide insecticidal agents |
GB9810671D0 (en) * | 1998-05-18 | 1998-07-15 | Pfizer Ltd | Anti-pruritic agents |
JP4511042B2 (en) | 1998-08-07 | 2010-07-28 | メルク セローノ ソシエテ アノニム | FSH mimics for the treatment of infertility |
BR0009322A (en) * | 1999-03-26 | 2002-04-30 | Euro Celtique Sa | Pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles replaced with aryl and their use |
DE19929076A1 (en) * | 1999-06-25 | 2000-12-28 | Aventis Pharma Gmbh | New indanyl-substituted benzenesulfonamide derivatives, as potassium channel blockers useful as safe antiarrhythmic agents, e.g. for treating atrial fibrillation or flutter |
US6355653B1 (en) * | 1999-09-06 | 2002-03-12 | Hoffmann-La Roche Inc. | Amino-triazolopyridine derivatives |
IL156487A0 (en) * | 2000-12-22 | 2004-01-04 | Astrazeneca Ab | Carbazole derivatives and their use as neuropeptide y5 receptor ligands |
US20020099035A1 (en) * | 2001-01-24 | 2002-07-25 | Sandanayaka Vincent P. | Method for preparing alpha-sulfonyl hydroxamic acid derivatives |
US7067539B2 (en) | 2001-02-08 | 2006-06-27 | Schering Corporation | Cannabinoid receptor ligands |
WO2002088089A1 (en) | 2001-04-19 | 2002-11-07 | Banyu Pharmaceutical Co., Ltd. | Spiropiperidine derivatives, nociceptin receptor antagonists containing the same as the active ingredient and medicinal compositions |
BR0213066A (en) * | 2001-10-04 | 2004-09-28 | Novartis Ag | Cyanoacetyl Compounds |
CA2465207C (en) * | 2001-11-01 | 2011-01-04 | Icagen, Inc. | Pyrazole-amides and -sulfonamides |
JP2003155285A (en) | 2001-11-19 | 2003-05-27 | Toray Ind Inc | Cyclic nitrogen-containing derivative |
CN1662496A (en) | 2002-06-19 | 2005-08-31 | 先灵公司 | Cannabinoid receptor agonists |
EP1581525A2 (en) | 2002-08-09 | 2005-10-05 | AstraZeneca AB | Compounds having an activity at metabotropic glutamate receptors |
EP1536790A2 (en) | 2002-08-09 | 2005-06-08 | AstraZeneca AB | Oxadiazoles as modulators of metabotropic glutamate receptor-5 |
UY27939A1 (en) | 2002-08-21 | 2004-03-31 | Glaxo Group Ltd | COMPOUNDS |
AR041268A1 (en) | 2002-09-19 | 2005-05-11 | Solvay Pharm Bv | DERIVED FROM 1H -1,2,4- TRIAZOL-3-CARBOXAMIDE THAT HAVE AGONIST, PARTIAL AGONIST, INVESTED AGONIST OR ANTAGONIST RECEIVER OF CANNABINOID CB 1 AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
GB0222495D0 (en) | 2002-09-27 | 2002-11-06 | Glaxo Group Ltd | Compounds |
CN1688557A (en) * | 2002-10-09 | 2005-10-26 | 辉瑞产品公司 | Thiazole compounds for treatment of neurodegenerative disorders |
WO2004042351A2 (en) | 2002-10-30 | 2004-05-21 | Merck & Co., Inc. | Piperidinyl-alpha-aminoamide modulators of chemokine receptor activity |
US7642277B2 (en) | 2002-12-04 | 2010-01-05 | Boehringer Ingelheim International Gmbh | Non-nucleoside reverse transcriptase inhibitors |
SE0300010D0 (en) | 2003-01-07 | 2003-01-07 | Astrazeneca Ab | Novel Compounds |
US7718692B2 (en) * | 2004-02-13 | 2010-05-18 | Carson John R | Hetero-substituted acetanilide derivatives as analgesic agents |
US7449464B2 (en) * | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
SE0301372D0 (en) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
BRPI0409721A (en) | 2003-05-12 | 2006-05-02 | Pfizer Prod Inc | isoxazole and isothiazole compounds for the treatment of neurodegenerative disorders |
JP2004337701A (en) * | 2003-05-14 | 2004-12-02 | Seiko Epson Corp | Method and apparatus for discharging liquid drop |
BRPI0413709A (en) * | 2003-08-21 | 2006-10-17 | Pfizer Prod Inc | compounds for the treatment of neurodegenerative disorders |
CA2538291A1 (en) | 2003-09-18 | 2005-03-31 | Merck & Co., Inc. | Substituted sulfonamides |
WO2005030127A2 (en) * | 2003-09-23 | 2005-04-07 | Merck & Co., Inc. | Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor |
AU2004283313A1 (en) | 2003-10-24 | 2005-05-06 | Exelixis, Inc. | TAO kinase modulators and methods of use |
US7820673B2 (en) * | 2003-12-17 | 2010-10-26 | Takeda Pharmaceutical Company Limited | Urea derivative, process for producing the same, and use |
WO2005077368A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
WO2005077373A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
WO2005077345A1 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Compounds for the treatment of gastro-esophageal reflux disease |
US7585881B2 (en) * | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
FR2866885B1 (en) * | 2004-02-26 | 2007-08-31 | Sanofi Synthelabo | PIPERIDINYLALKYLCARBAMATES DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF |
US20070185152A1 (en) | 2004-03-02 | 2007-08-09 | Smithkline Beecham Corporation | Inhibitors of akt activity |
RS50595B (en) * | 2004-03-23 | 2010-05-07 | Pfizer Products Incorporated | Imidazole compounds for the treatment of neurodegenerative disorders |
US7232820B2 (en) * | 2004-04-01 | 2007-06-19 | Pfizer Inc | Thiadiazole-amine compounds for the treatment of neurodegenerative disorders |
WO2005121758A1 (en) * | 2004-06-03 | 2005-12-22 | Ciphergen Biosystems, Inc. | Biomarkers for peripheral artery disease |
US20050288338A1 (en) | 2004-06-24 | 2005-12-29 | Wenqing Yao | Amido compounds and their use as pharmaceuticals |
FR2872813B1 (en) | 2004-07-09 | 2007-01-19 | Sanofi Synthelabo | 2-CARBAMID-4-PHENYLTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
CA2580409C (en) | 2004-09-16 | 2013-08-13 | Astellas Pharma Inc. | Triazole derivative or salt thereof |
WO2006044645A2 (en) * | 2004-10-13 | 2006-04-27 | Adolor Corporation | Sulfamoyl benzamides and methods of their use |
TW200843761A (en) * | 2004-10-28 | 2008-11-16 | Shionogi & Co | 3-carbamoyl-2-pyridone derivatives |
NZ555320A (en) | 2004-12-03 | 2010-11-26 | Schering Corp | Substituted piperazines as CB1 antagonists |
EP2368881A1 (en) | 2005-01-10 | 2011-09-28 | University of Connecticut | Heteropyrazole analogs acting on cannabinoid receptors |
WO2006080040A1 (en) | 2005-01-25 | 2006-08-03 | Università Degli Studi Di Siena | New potent and selective ligands of cannabinoid receptors |
GB0504753D0 (en) | 2005-03-08 | 2005-04-13 | Astrazeneca Ab | Chemical compounds |
GB0506133D0 (en) | 2005-03-24 | 2005-05-04 | Sterix Ltd | Compound |
FR2885364B1 (en) * | 2005-05-03 | 2007-06-29 | Sanofi Aventis Sa | ALKYL-, ALKENYL- AND ALKYNYLCARBAMATES DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
WO2007020502A2 (en) | 2005-08-16 | 2007-02-22 | Pharmacia & Upjohn Company Llc | Cannabinoid receptor ligands and uses thereof |
CA2628844C (en) | 2005-11-08 | 2011-12-06 | Pfizer Limited | Pyrazole derivatives and their medical use |
WO2007070760A2 (en) | 2005-12-15 | 2007-06-21 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
US20110034454A1 (en) | 2006-01-11 | 2011-02-10 | Allan Paul Dishington | Morpholino pyrimidine derivatives and their use in therapy |
WO2007101270A1 (en) * | 2006-03-02 | 2007-09-07 | Incyte Corporation | MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME |
JP2009536918A (en) | 2006-03-06 | 2009-10-22 | ファイザー株式会社 | Sulfonylbenzimidazole derivatives |
EP2007707A1 (en) * | 2006-04-07 | 2008-12-31 | Boehringer Ingelheim International GmbH | Compounds which modulate the cb2 receptor |
BRPI0712720A2 (en) | 2006-05-31 | 2012-11-20 | Abbott Lab | thiazide compounds as cannabinoid receptor ligands and uses thereof |
KR101435231B1 (en) | 2006-08-24 | 2014-10-02 | 아스트라제네카 아베 | Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders |
WO2008048914A1 (en) | 2006-10-17 | 2008-04-24 | Boehringer Ingelheim International Gmbh | Polycyclic compounds which modulate the cb2 receptor |
US8173638B2 (en) * | 2006-11-21 | 2012-05-08 | Boehringer Ingelheim International Gmbh | Compounds which modulate the CB2 receptor |
WO2008098025A1 (en) | 2007-02-08 | 2008-08-14 | Boehringer Ingelheim International Gmbh | Arylsulfonamide compounds which modulate the cb2 receptor |
JP5491871B2 (en) | 2007-02-28 | 2014-05-14 | アドビナス セラピュティックス プライベート リミテッド | 2,2,2-Trisubstituted acetamide derivatives as glucokinase activators, methods and pharmaceutical applications thereof |
CN101686989B (en) * | 2007-06-21 | 2016-10-19 | 卡拉治疗学股份有限公司 | Substituted imidazoheterocycles |
EP2215080A1 (en) | 2007-10-25 | 2010-08-11 | Boehringer Ingelheim International GmbH | Diazepane compounds which modulate the cb2 receptor |
EP2217565B1 (en) * | 2007-11-07 | 2013-05-22 | Boehringer Ingelheim International GmbH | Compounds which modulate the cb2 receptor |
ES2574130T3 (en) | 2007-12-17 | 2016-06-15 | Janssen Pharmaceutica, N.V. | Fluoroalkyl substituted benzimidazoles as cannabinoid agonists |
EP2219646A4 (en) * | 2007-12-21 | 2010-12-22 | Univ Rochester | Method for altering the lifespan of eukaryotic organisms |
CA2724232A1 (en) | 2008-05-13 | 2009-11-19 | Boehringer Ingelheim International Gmbh | Sulfone compounds which modulate the cb2 receptor |
US8178568B2 (en) * | 2008-07-10 | 2012-05-15 | Boehringer Ingelheim International Gmbh | Sulfone compounds which modulate the CB2 receptor |
KR20110063438A (en) * | 2008-09-25 | 2011-06-10 | 베링거 인겔하임 인터내셔날 게엠베하 | Sulfonyl compounds which selectively modulate the cb2 receptor |
US8629157B2 (en) * | 2009-01-05 | 2014-01-14 | Boehringer Ingelheim International Gmbh | Pyrrolidine compounds which modulate the CB2 receptor |
JP5705748B2 (en) * | 2009-02-18 | 2015-04-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Heterocyclic compounds that modulate the CB2 receptor |
US8299103B2 (en) | 2009-06-15 | 2012-10-30 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
US8383615B2 (en) * | 2009-06-16 | 2013-02-26 | Boehringer Ingelheim International Gmbh | Azetidine 2-carboxamide derivatives which modulate the CB2 receptor |
JP2013505295A (en) * | 2009-09-22 | 2013-02-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Compound that selectively modulates CB2 receptor |
JP2013517271A (en) | 2010-01-15 | 2013-05-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Compounds that modulate the CB2 receptor |
JP5746228B2 (en) | 2010-03-05 | 2015-07-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Tetrazole compound that selectively modulates CB2 receptor |
US8846936B2 (en) | 2010-07-22 | 2014-09-30 | Boehringer Ingelheim International Gmbh | Sulfonyl compounds which modulate the CB2 receptor |
-
2010
- 2010-06-01 US US12/791,213 patent/US8299103B2/en active Active
- 2010-06-08 EP EP13196679.8A patent/EP2716635B1/en active Active
- 2010-06-08 KR KR1020117029859A patent/KR20120047211A/en not_active Application Discontinuation
- 2010-06-08 BR BRPI1011668A patent/BRPI1011668A2/en not_active Application Discontinuation
- 2010-06-08 AU AU2010260397A patent/AU2010260397A1/en not_active Abandoned
- 2010-06-08 JP JP2012516122A patent/JP5492297B2/en active Active
- 2010-06-08 CN CN2010800248806A patent/CN102803235A/en active Pending
- 2010-06-08 EA EA201200019A patent/EA201200019A1/en unknown
- 2010-06-08 CA CA2765525A patent/CA2765525A1/en not_active Abandoned
- 2010-06-08 EP EP10723895A patent/EP2443100A2/en not_active Withdrawn
- 2010-06-08 MA MA34453A patent/MA33362B1/en unknown
- 2010-06-08 MX MX2011013152A patent/MX2011013152A/en active IP Right Grant
- 2010-06-08 WO PCT/US2010/037697 patent/WO2010147792A2/en active Application Filing
- 2010-06-08 AP AP2011005988A patent/AP2011005988A0/en unknown
- 2010-06-08 PE PE2011002084A patent/PE20120561A1/en not_active Application Discontinuation
- 2010-06-08 SG SG2011092871A patent/SG176864A1/en unknown
- 2010-06-14 TW TW099119339A patent/TW201111374A/en unknown
- 2010-06-14 AR ARP100102105A patent/AR077362A1/en unknown
-
2011
- 2011-11-10 ZA ZA2011/08258A patent/ZA201108258B/en unknown
- 2011-11-14 IL IL216348A patent/IL216348A0/en unknown
- 2011-12-14 TN TNP2011000639A patent/TN2011000639A1/en unknown
- 2011-12-14 CL CL2011003160A patent/CL2011003160A1/en unknown
- 2011-12-15 CO CO11173246A patent/CO6470896A2/en not_active Application Discontinuation
-
2012
- 2012-01-07 EC EC2012011583A patent/ECSP12011583A/en unknown
- 2012-09-26 US US13/627,149 patent/US8735430B2/en active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994007607A1 (en) | 1992-09-29 | 1994-04-14 | Boehringer Ingelheim International Gmbh | Atomising nozzle and filter and spray generating device |
WO1997012687A1 (en) | 1995-10-04 | 1997-04-10 | Boehringer Ingelheim International Gmbh | Device of miniaturised construction for producing high pressure in a fluid to be atomised |
WO1997012683A1 (en) | 1995-10-04 | 1997-04-10 | Boehringer Ingelheim International Gmbh | Device for mounting a component exposed to a pressurized fluid |
WO1997020590A1 (en) | 1995-12-05 | 1997-06-12 | Boehringer Ingelheim International Gmbh | Locking mechanism for a spring-actuated device |
WO2008014199A2 (en) | 2006-07-28 | 2008-01-31 | Boehringer Ingelheim International Gmbh | Sulfonyl compounds which modulate the cb2 receptor |
WO2008039645A1 (en) | 2006-09-25 | 2008-04-03 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
WO2009105509A1 (en) | 2008-02-21 | 2009-08-27 | Boehringer Ingelheim International Gmbh | Amine and ether compounds which modulate the cb2 receptor |
Non-Patent Citations (6)
Title |
---|
"Handbook ofPharmaceutical Additives", 1995, GOWER |
A. GENNARO: "Remington: The Science and Practice of Pharmacy,20th Edition,", 2000, LIPPINCOTT WILLIAMS & WILKINS |
A.H. KIBBE: "Handbook of Pharmaceutical Excipients", 2000, AMERICAN PHARMACEUTICAL ASS'N |
EXPERT OPINION ON INVESTIGATIONAL DRUGS, vol. 14, no. 6, 2005, pages 695 - 703 |
GOSH, A.K. ET AL., J MED. CHEM., vol. 36, 1993, pages 2300 - 2310 |
H.C. ANSEL; N.G. POPOVISH: "Pharmaceutical Dosage Forms and Drug Delivery Systems, 5th ed.,", 1990, LEA AND FEBIGER |
Cited By (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8299111B2 (en) | 2006-07-28 | 2012-10-30 | Boehringer Ingelheim International Gmbh | Compounds which modulate the CB2 receptor |
US7928123B2 (en) | 2006-09-25 | 2011-04-19 | Boehringer Ingelheim International Gmbh | Compounds which modulate the CB2 receptor |
US8829034B2 (en) | 2006-09-25 | 2014-09-09 | Boehringer Ingerlheim International GmbH | Compounds which modulate the CB2 receptor |
US7928103B2 (en) | 2006-10-17 | 2011-04-19 | Boehringer Ingelheim International Gmbh | Compounds which modulate the CB2 receptor |
US8173638B2 (en) | 2006-11-21 | 2012-05-08 | Boehringer Ingelheim International Gmbh | Compounds which modulate the CB2 receptor |
US8546563B2 (en) | 2007-11-07 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Compounds which modulate the CB2 receptor |
US8957063B2 (en) | 2008-02-21 | 2015-02-17 | Boehringer Ingelheim International Gmbh | Amine and ether compounds which modulate the CB2 receptor |
US8178568B2 (en) | 2008-07-10 | 2012-05-15 | Boehringer Ingelheim International Gmbh | Sulfone compounds which modulate the CB2 receptor |
US8349871B2 (en) | 2008-09-25 | 2013-01-08 | Boehringer Ingelheim International Gmbh | Therapeutic uses of compounds which selectively modulate the CB2 receptor |
US8362039B2 (en) | 2008-09-25 | 2013-01-29 | Boehringer Ingelheim International Gmbh | Therapeutic uses of compounds which selectively modulate the CB2 receptor |
US8372874B2 (en) | 2008-09-25 | 2013-02-12 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
US8048899B2 (en) | 2008-09-25 | 2011-11-01 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
US8629157B2 (en) | 2009-01-05 | 2014-01-14 | Boehringer Ingelheim International Gmbh | Pyrrolidine compounds which modulate the CB2 receptor |
US8889670B2 (en) | 2009-02-18 | 2014-11-18 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds which modulate the CB2 receptor |
US8299103B2 (en) | 2009-06-15 | 2012-10-30 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
US9115139B2 (en) | 2009-06-15 | 2015-08-25 | Takeda Pharmaceutical Company Limited | Pyrazinooxazepine derivatives |
US8735430B2 (en) | 2009-06-15 | 2014-05-27 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
US8383615B2 (en) | 2009-06-16 | 2013-02-26 | Boehringer Ingelheim International Gmbh | Azetidine 2-carboxamide derivatives which modulate the CB2 receptor |
US8383651B2 (en) | 2009-09-22 | 2013-02-26 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
US8754113B2 (en) | 2009-12-15 | 2014-06-17 | Shionogi & Co., Ltd. | Oxadiazole derivative having endothelial lipase inhibitory activity |
EP2514749A4 (en) * | 2009-12-15 | 2013-04-17 | Shionogi & Co | Oxadiazole derivative having endothelial lipase inhibitory activity |
EP2514749A1 (en) * | 2009-12-15 | 2012-10-24 | Shionogi & Co., Ltd. | Oxadiazole derivative having endothelial lipase inhibitory activity |
US9315454B2 (en) | 2010-01-15 | 2016-04-19 | Boehringer Ingelheim International Gmbh | Compounds which modulate the CB2 receptor |
US8329735B2 (en) | 2010-03-05 | 2012-12-11 | Boehringer Ingelheim International Gmbh | Tetrazole compounds which selectively modulate the CB2 receptor |
US8846936B2 (en) | 2010-07-22 | 2014-09-30 | Boehringer Ingelheim International Gmbh | Sulfonyl compounds which modulate the CB2 receptor |
JP2016522195A (en) * | 2013-05-17 | 2016-07-28 | セントレキション・セラピューティクス・コーポレーションCentrexion Therapeutics Corporation | Novel (cyano-dimethyl-methyl) -isoxazole and-[1,3,4] thiadiazole |
WO2014184327A1 (en) | 2013-05-17 | 2014-11-20 | Boehringer Ingelheim International Gmbh | Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
EP2803668A1 (en) | 2013-05-17 | 2014-11-19 | Boehringer Ingelheim International Gmbh | Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
US8865744B1 (en) | 2013-05-17 | 2014-10-21 | Boehringer Ingelheim International Gmbh | (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
US9650370B2 (en) | 2013-05-17 | 2017-05-16 | Centrexion Therapeutics Corporation | (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
AU2014267197B2 (en) * | 2013-05-17 | 2018-07-19 | Centrexion Therapeutics Corporation | Novel (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
US10112934B2 (en) | 2013-05-17 | 2018-10-30 | Centrexion Therapeutics Corporation | (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
EA031021B1 (en) * | 2013-05-17 | 2018-11-30 | Сентрекшн Терапьютикс Корпорейшн | Novel (cyano-dimethyl-methyl)isoxazoles and -[1,3,4]thiadiazoles |
US10570125B2 (en) | 2013-05-17 | 2020-02-25 | Centrexion Therapeutics Corporation | (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
US11084810B2 (en) | 2013-05-17 | 2021-08-10 | Centrexion Therapeutics Corporation | (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
US11725004B2 (en) | 2013-05-17 | 2023-08-15 | Centrexion Therapeutics Corporation | (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
Also Published As
Publication number | Publication date |
---|---|
KR20120047211A (en) | 2012-05-11 |
MA33362B1 (en) | 2012-06-01 |
ECSP12011583A (en) | 2012-02-29 |
WO2010147792A3 (en) | 2011-09-01 |
US8299103B2 (en) | 2012-10-30 |
CO6470896A2 (en) | 2012-06-29 |
CL2011003160A1 (en) | 2012-08-03 |
JP5492297B2 (en) | 2014-05-14 |
AP2011005988A0 (en) | 2011-12-31 |
MX2011013152A (en) | 2012-01-20 |
SG176864A1 (en) | 2012-02-28 |
EP2716635A1 (en) | 2014-04-09 |
EP2716635B1 (en) | 2017-02-01 |
CA2765525A1 (en) | 2010-12-23 |
BRPI1011668A2 (en) | 2016-03-22 |
CN102803235A (en) | 2012-11-28 |
US8735430B2 (en) | 2014-05-27 |
TN2011000639A1 (en) | 2013-05-24 |
AU2010260397A1 (en) | 2011-12-08 |
US20130030022A1 (en) | 2013-01-31 |
AR077362A1 (en) | 2011-08-24 |
IL216348A0 (en) | 2012-01-31 |
JP2012530138A (en) | 2012-11-29 |
PE20120561A1 (en) | 2012-05-19 |
ZA201108258B (en) | 2012-07-25 |
EP2443100A2 (en) | 2012-04-25 |
EA201200019A1 (en) | 2012-06-29 |
US20110136869A1 (en) | 2011-06-09 |
TW201111374A (en) | 2011-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2716635B1 (en) | Compounds which selectively modulate the CB2 receptor | |
EP2542539B1 (en) | Tetrazole compounds which selectively modulate the cb2 receptor | |
EP2342199B1 (en) | Sulfonyl compounds which selectively modulate the CB2 receptor | |
EP2265585B1 (en) | Amine and ether compounds which modulate the cb2 receptor | |
US8383651B2 (en) | Compounds which selectively modulate the CB2 receptor | |
EP2418207A1 (en) | Sulfone compounds which modulate the CB2 receptor | |
WO2010096371A2 (en) | Heterocyclic compounds which modulate the cb2 receptor | |
WO2010077836A2 (en) | Pyrrolidine compounds which modulate the cb2 receptor | |
EP2443107A1 (en) | Azetidine 2 -carboxamide derivatives which modulate the cb2 receptor | |
EP2326629A1 (en) | Sulfone compounds which modulate the cb2 receptor | |
WO2012012307A9 (en) | Sulfonyl compounds which modulate the cb2 receptor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080024880.6 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10723895 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010260397 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2010260397 Country of ref document: AU Date of ref document: 20100608 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2011/013152 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 002084-2011 Country of ref document: PE |
|
ENP | Entry into the national phase |
Ref document number: 20117029859 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2765525 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012516122 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11173246 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10240/DELNP/2011 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: A201200322 Country of ref document: UA Ref document number: 2010723895 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12532 Country of ref document: GE Ref document number: 201200019 Country of ref document: EA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: PI1011668 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: PI1011668 Country of ref document: BR Kind code of ref document: A2 Effective date: 20111214 |